Broad applicability of nivolumab in melanoma regardless of BRAF mutation status
A partir de données issues de 4 essais cliniques ayant inclus un total de 440 patients atteints d'un mélanome non résécable de stade III ou IV, cette étude évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du nivolumab en fonction de la présence ou de l'absence d'un gène BRAF muté
Given the availability of several new active therapies, the identification of subsets of patients who may be more or less likely to benefit from any agent or class of agents is important for clinical decision making. In this issue of JAMA Oncology, Larkin et al1 examine the activity of nivolumab in the subsets of patients with and without a BRAF V600–activating mutation. In a retrospective analysis of 4 clinical trials including 334 patients with BRAF wild-type melanoma and 106 who were positive for the BRAF V600 mutation, the authors suggest that there are no differences in adverse events, objective response rates, time to response, or duration of responses to nivolumab in patients with advanced melanoma, with or without the BRAF mutation. The objective response rate was 34.6% for patients with wild-type BRAF melanoma and 29.7% for those with mutant BRAF melanoma, suggesting that nivolumab had similar efficacy and safety outcomes regardless of BRAF mutation status in the study population.
JAMA Oncology , commentaire en libre accès, 2014